---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-006798"
form_type: "8-K"
ticker: "IVF"
cik: "0001417926"
company_name: "INVO Fertility, Inc."
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T02:12:33.472604+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# INVO Fertility reports 116% revenue growth to $6.5M in FY2024; adjusted EBITDA improves to $(2.2)M

## Summary
- Q4 2024 revenue $1.69M (+22% YoY); full-year revenue $6.53M (+116% YoY).
- Net loss widened to $(9.1)M in FY2024 from $(8.0)M, driven by NAYA Therapeutics merger costs.
- Adjusted EBITDA improved to $(2.2)M in FY2024 from $(4.9)M in FY2023.
- Company announced intent to divest majority stake in NAYA TX to refocus on fertility clinic operations.
- Management cites declining U.S. fertility rate and rising ART demand as expansion catalysts.

## SEC filing metadata
- accession: 0001641172-25-006798
- form_type: 8-K
- ticker: IVF
- cik: 0001417926
- company_name: INVO Fertility, Inc.
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1417926/000164117225006798/0001641172-25-006798-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1417926/000164117225006798/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-006798
- JSON: https://secwatch.observer/filing/0001641172-25-006798.json
- Plain text: https://secwatch.observer/filing/0001641172-25-006798.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.